INTRODUCTION
============

Endoscopic retrograde cholangiopancreatography (ERCP) is one of the most effective techniques in the diagnosis and treatment of biliary ducts and pancreas disorders.[@ref1] However, this technique is accompanied by certain complications and among them, pancreatitis is the most common and serious ones. Post-ERCP pancreatitis (PEP) identified as clinical signs of acute pancreatitis after ERCP with elevated levels of pancreatic enzymes.[@ref2] Despite significant advances in endoscopic technology, a subsidiary of ERCP and learn how to use it, the prevalence of PEP is steady during the past 30 years.[@ref3] Incidence of PEP is varied from 0.4% to 5.4% of patients depending on the risk factors and the indication of ERCP[@ref4] and totally 0.4-0.6% of patients showed severe PEP which needs endoscopic or surgical interventions.[@ref5] Diagnosis of PEP is based on both clinical and laboratory findings and defined and characterized mostly using Cotton criteria. Mild PEP is defined as abdominal pain that needs hospitalization or hospitalization's extension for 2-3 days and elevation of serum amylase activity more than 3 times over the upper limit of normal 24 hours after ERCP. Moderate and severe PEP are defined by the hospitalization period of 4-10 and more than 10 days, respectively. Also, severe PEP is accompanied by certain complications such as necrosis or pseudocyst and sometimes need drainage or surgery as interventions. [@ref6]

Although several endoscopic and pharmacologic strategies have been reported for prevention or reducing the occurrence of PEP,[@ref7][@ref8][@ref9][@ref10][@ref11][@ref12][@ref13]-[@ref14] there are controversies about their effectiveness. In the present study, we aimed to evaluate and compare the therapeutic effects of administration of naproxen as a suppository, isosorbide dinitrate as sublingual and their combination in the prevention of PEP.

MATERIALS AND METHODS
=====================

Patients
--------

In a double-blinded randomized clinical trial (IRCT 201409251155N22), all patients with age more than 16 years who referred for ERCP to Gastroenterology ward of Razi hospital as a referral center of the Rasht, the capital of Guilan province, from June 2015 to February 2016 were enrolled. Patients with acute pancreatitis in the recent two weeks, history of chronic pancreatitis, previous sphincterotomy, consumption of non-steroidal anti-inflammatory drugs (NSAIDs) or nitrate in the recent week, and contraindications of administration of NSAIDs or nitrate such as renal failure, peptic ulcer with recent hemorrhage, hypotension, sensitivity to one of both drugs and lack of satisfaction to precipitation in the study were excluded. The sample size of 202 patients for each group was calculated based on the previous report[@ref15] and consideration of *p*=0.06, α=0.05, and β=0.1 using the following formula:

$$N = \frac{{2(Z_{1 - \frac{\alpha}{2}} + Z_{1\operatorname{-\beta}})}^{2}{(P_{2} - P_{1})}}{{(P_{1} - P_{2})}^{2}}$$

After providing informed consent, randomization was performed using a random block ([https://www.sealedenvelope*.com/simple-randomiser/v1*/lists](https://www.sealedenvelope.com/simple-randomiser/v1/lists)). Patients, physicians, and nurses who administered treatment were unaware of the nature of the drugs. The protocol was approved by the Ethical Committee of Guilan University of Medical Sciences (Reference number: 1930175708) and followed the Helsinki Declaration of 1975, as revised in 2000 (available at <http://www.wma.net/e/policy/17-c_e.html>).

Grouping and interventions
--------------------------

Totally, 606 patients were allocated into groups A, B, and C, respectively and received the following treatments immediately before the ERCP:

1.  •Group A: 500 mg rectal suppository naproxen (Behvazan Co., Iran)

2.  •Group B: 5 mg sublingual isosorbide dinitrate (UCB Pharma GmbH, Germany)

3.  •Group C: 5 mg sublingual isosorbide dinitrate and 500 mg rectal suppository naproxen

ERCP was done using a standard therapeutic duodenoscope (EXERA CV-160, Olympus CO.) when the patient was under local anesthesia with 2% lidocaine and after premedication by intravenous administration of 0.05 mg/ kg of Midazolam or in cases with a contraindication, intravenous administration of 1 mg/kg pethidine. This condition was indefeasible, except in certain cases, that needs changes. Blood pressure, heart rate, and oxygen saturation were monitored routinely. Contrast medium (Meglumine Compound 76%) was injected manually, under fluoroscopic guidance and experienced endoscopists carried out ERCPs.

In Group A, 6 patients and in Group B 15 patients failed ERCP. The reasons for technical and clinical failure of ERCP in both groups were mucosal edema, chronic duodenal ulcer disease, impacted stones, tumor infiltration due to pancreatic cancer, periampullary diverticulum, cardiac arrhythmia and poor cooperation of patient. After excluding patients who were not eligible for analysis, 196, 187 and 202 patients (totally 585 *patients*) were included in groups A, B, and C, respectively

Assessments
-----------

Pancreatitis and its severity were defined based on Cotton criteria[@ref6] as the onset of pain in the upper abdomen and increase of serum amylase activity more than 3 times over the upper normal limit (60-100 IU/L) within first the 24 h post-ERCP. The severity of pancreatitis categorized based on the duration of treatment for PEP as mild (2-3 day), moderate (4-10 day) and severe (more than 10 days and/or necessitated surgical or intensive treatment, or contributed to death).

Demographic information includes age and gender plus risk factors, ERCP elements, and follow-up data were collected at the time of the procedure, 2 and 24 hrs after ERCP. Oral intake was allowed for patients who had normal serum amylase after 2 hrs and showed no history of abdominal pain, nausea, and vomiting. ERCP duration, the number of biliary and pancreatic cannulations, findings of the biliary and/or pancreatic duct, presence or absence of juxta-ampullary diverticulum and interventions were recorded. Finally, patients with persistent pancreatitis symptoms more than 48 hrs were evaluated for pancreatitis complications such as abscess, pseudocyst, or fluid collection by CT-scanning.

Statistical analysis
--------------------

Qualitative and quantitative data were reported as frequency (percentage) and mean±SD, respectively. Data were analyzed using IBM SPSS Statistics version 23. Associations between qualitative variables were checked using the Chi-square test. One way analysis of variance (ANOVA) was used to compare quantitative data between three groups and Tukey was used as Post-hoc test. *p*\< 0.05 was considered a significant difference.

RESULTS
=======

Totally, 196 (33.5%), 187 (32%) and 202 (34.5%) patients were assessed in groups A, B, and C, respectively. The three groups were age-, sex-, and body mass index (BMI)-matched (*p*\>0.05, [Table 1](#T1){ref-type="table"}). The most common reason for ERCP in our patients was common bile duct stone (370 patients, 63.2%).

No significant differences were detected between three groups about amylase level before ERCP (*p*=0.147), after 2 hrs (*p*=0.396) and after 24 hrs (*p*=0.808). Also, no significant associations between post-ERCP abdominal pain (*p*=0.328) and pancreatitis (*p*=0.845) with types of treatment were observed. Although severe pancreatitis included the lowest and mild pancreatitis included the highest percentages of patients with pancreatitis in all three groups, but this difference in the severity of pancreatitis was not statistically significant (*p*=0.647, [Table 2](#T2){ref-type="table"}). Just one patient died in the follow-up who belonged to sublingual isosorbide dinitrate. All other patients were discharged in good condition without reported side effects.

Incidence of PEP based on different categories in the three groups is presented in [Table 3](#T3){ref-type="table"}. Higher incidences of PEP was seen in patients of rectal suppository group (group A) who used diazepam & pethidine as anesthetic drugs (*p*=0.027) and had four or more attempts to cannulate the papilla (*p*\<0.001).

Although no significant differences were detected in the incidence of PEP based on groups and categorized ERCP duration, patients with PEP had higher ERCP time in comparison to patients without PEP (42.25±14.88 min vs. 37.67±15.25 min respectively, *p*=0.013).

Totally, we found that 80 patients (13.7%) suffered from PEP. Comparisons of PEP occurrence based on different patient- and procedure-related variables are presented in [Figs. 1](#F1){ref-type="fig"}, [2](#F2){ref-type="fig"}, respectively. No significant associations were detected between sex, age and BMI with the occurrence of PEP (*p*=0.055, *p*=0.056, and *p*=0.873, respectively). Among procedure-related variables, patients with pancreatic duct injection (*p*=0.013), using pancreatic stent (*p*=0.004), equal or more than 4 pancreatic ducts cannulation (*p*\<0.001), ERCP duration of 60-80 min (*p*=0.041), and anesthetized with diazepam (*p*=0.033) were mostly suffered from PEP ([Fig. 3](#F3){ref-type="fig"}).

DISCUSSION
==========

In the present RCT, it has been shown that howbeit totally PEP incidence was not changed in response to our administered agents, the frequency of PEP was higher in patients of rectal suppository group without pancreatic duct injection who used Diazepam & Pethidine as anesthetic drugs with four or more attempts to cannulate the papilla in comparison to other two groups. If all patients considered totally and ignored the patients' groups, pancreatic duct injection, using a pancreatic stent, equal or more than 4 pancreatic ducts cannulation, ERCP duration of 60-80 min, using other methods of sphincterotomy rather than needle-knife, precut or sphincterotomy and anesthetizing with diazepam were predisposed patients to PEP.

Pancreatitis is the most usual severe complication of ERCP.[@ref4] Our PEP incidence (13.7%) is slightly higher in comparison to those reported in the systematic review as 3-10%. However, they reported rates can increase to 15% or more in high patient- and procedure-related at risks populations.[@ref16] To prevent PEP some strategies must be attended. These include selecting patients carefully, training of GI man, considering of alternative methods, cannulation under the guide of wire for all patients and using pancreatic duct stent and a single dose of rectal NSAIDs such as indomethacin or diclofenac for high-risk patients.[@ref17] For the first time, Elmunzer et al.[@ref18] reported that using rectal indomethacin as a nonsteroidal anti-inflammatory drug (NSAID) could decrease the rate of PEP near 8% (9.2% vs. 16.9%) in comparison to placebo. Indeed, NSAIDs inhibit some of the important inflammatory enzymes like cyclooxygenase and phospholipase A2.[@ref16] After them, several studies were performed about the effects of NSAIDs application in the prevention of PEP with supportive or opposite findings. For instance, in opposite to Elmunzer et al.,[@ref18] Levenick et al.[@ref19] in a double-blind randomized controlled clinical trial found that rectal indomethacin did not prevent PEP in consecutive patients. Also, the protective efficacy of rectal indomethacin against PEP just confirmed in high-risk patients,[@ref20],[@ref21] rejected in moderate[@ref20] and low-risk patients.[@ref22] In a meta-analysis of 6 studies with more than 2400 patients, no significant difference was obtained between indomethacin and placebo administration before ERCP in overall, moderate to severe and mild rates of PEP (OR: 0.67, 0.66 and 0.71, respectively).[@ref23] In another systematic review of 16 RCTs with a total number of 6458 patients that evaluated the efficacy of rectal NSAIDs with placebo or no treatment in the prevention of PEP, it has been confirmed that rectal NSAIDs decreased the overall risk of PEP.[@ref24] Moreover, reduce the risk ratio, a number of patients needed to treat, and the decrease of risk ration of moderate to severe PEP by using indomethacin and diclofenac is confirmed by a meta-analysis of 17 trials with the total number of 4741 patients.[@ref25] Furthermore, among the NSAIDs, diclofenac was acted better than indomethacin[@ref24] and naproxen.[@ref26] Howbeit some controversies have existed about the superiority of diclofenac against other NSAIDs.[@ref25][@ref26]-[@ref27] We also previously in a double-blind RCT reported that single suppository dose of 500 mg naproxen, as another member of NSAIDs, immediately before ERCP decreased the rate of PEP.[@ref28] Based on all of the above mentioned shreds of evidence, it seems that rectal NSAIDs are effective and safe in the prevention of PEP in all levels of risk. However, our findings of the effectiveness of naproxen as one of the NSAIDs are mostly similar to those reported by Levenick et al.[@ref19] which showed that using naproxen had no beneficial in comparison to other treatments and some cases with special conditions, the rate of PEP was more in the groups who received rectal suppository naproxen.

Despite NSAIDs, there are some other medications, which evaluated their efficacy in the prevention of PEP. These include nitrates,[@ref29][@ref30]-[@ref31] protease inhibitors,[@ref13],[@ref32] somatostatin,[@ref33] heparin,[@ref11] allopurinol,[@ref8],[@ref34] secretin,[@ref14] epinephrine,[@ref10] neurokinin-1 receptor antagonist,[@ref7] anti-tumor necrosis factor-a (TNF-a) agent,[@ref12] b-carotene,[@ref9] and intravenous fluid hydration.[@ref35] One of them is nitrate which administrated through different routes and provides conflicting results ranged from a significant decline[@ref29],[@ref30] to no specific effects[@ref36] on the occurrence of PEP. The basic mechanism of nitrate's effectiveness is through papillary relaxation and simulate PD placement.[@ref37] Although the use of nitrates for prevention of PEP is limited due to lack of their efficacy and having serious side effects,[@ref29],[@ref38] one of the recent studies advised the use of nitrates in co-administration with NSAIDs to provide better results of both of them.[@ref31] We found no significant differences in the occurrence of PEP between three groups and therefore, it can be said that using of sublingual isosorbide dinitrate is effective in the prevention of PEP as well as rectal suppository naproxen and their combination.

As another important finding, a positive association between using pancreatic stent and occurrence of PEP regardless of patients groups was detected. Although, several studies reported that pancreatic stent placement prevented PEP, but it seems that there is controversy in its effectiveness yet. Pancreatic stent placement related adverse events is reported about 4%.[@ref39][@ref40]-[@ref41] Moreover, in two almost old studies, stent-induced ductal alterations were introduced as cause of chronic pancreatitis-like changes.[@ref42],[@ref43] In light of our additional data about the significant positive relationship between stent and PEP and also based on previous reported chronic pancreatitis as stent complication, we suggested performing the updated study as systematic review and/or meta-analysis covering all newly published RCTs. This can clearly reveal whether post- ERCP pancreatic stent placement is beneficial for the prevention of PEP or not.

In conclusion, it can be said that prophylactic naproxen suppository or isosorbide dinitrate sublingually or co-administration had no significant difference in the prevention and severity of PEP, however, enhancing the endoscopist's skills can be effective. Departments and educational hospitals should develop their assessment and quality assurance measures for the training of fellows' not only technical training but also an understanding of the diagnostic and therapeutic roles of the procedure including of the indications, risks, benefits, limitations, contraindications, possible adverse events, alternatives to the procedure.
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###### 

Comparison of mean±SD and frequency (%) of age, BMI and sex between three groups

  Parameters                             Group A (n=196)   Group B (n=187)   Group C (n=202)   *p*-value
  -------------------------- ----------- ----------------- ----------------- ----------------- -----------
  Age (years) (mean ±SD)                 61.36±18.23       61.05±18.18       61.90±17.04       0.892
  BMI (kg/m^2^) (mean ±SD)               26.50±15.38       24.48±4.79        25.04±5.91        0.165
  Sex n (%)                  Female      128 (65.3)        105 (56.1)        127 (62.9)        0.164
  Male                       68 (34.7)   82 (43.9)         75 (37.1)                           

Group A, 500 mg rectal suppository naproxen; Group B, 5 mg sublingual isosorbide dinitrate; Group C, 5 mg sublingual isosorbide dinitrate and 500 mg rectal suppository naproxen

###### 

Comparison of frequency (percentage) of pancreatitis, severity of pancreatitis and abdominal pain between three groups

  Parameters                       Group A (n=196)   Group B (n=187)   Group C (n=202)   *p*-value
  -------------------------------- ----------------- ----------------- ----------------- -----------
  Pancreatitis n (%)                                                                     0.845
  Yes (n=80)                       29 (14.8)         24 (12.8)         27 (13.4)         
  No (n=505)                       167 (85.2)        163 (87.2)        175 (86.6)        
  Severity of pancreatitis n (%)                                                         0.647
  Mild (n=51)                      16 (55.2)         17 (70.8)         18 (66.7)         
  Moderate (n=21)                  10 (34.5)         4 (16.7)          7 (25.9)          
  Severe (n=8)                     3 (10.3)          3 (12.5)          2 (7.4)           
  Abdominal pain n (%)                                                                   0.328
  Yes (n=78)                       26 (13.3)         30 (16.0)         22 (10.9)         
  No (n=507)                       170 (86.7)        157 (84.0)        180 (89.1)        

Group A, 500 mg rectal suppository naproxen; Group B, 5 mg sublingual isosorbide dinitrate; Group C, 5 mg sublingual isosorbide dinitrate and 500 mg rectal suppository naproxen

###### 

Incidence of post-ERCP pancreatitis based on different categorized variables

  Variables                                                               Group A 196 (%)   Group B 187 (%)   Group C 202 (%)   *p*-value
  --------------------------------------------- ------------------------- ----------------- ----------------- ----------------- -----------
  n (%)                                         Pancreatitis: 80 (13.7)   29 (14.8)         24 (12.8)         27 (13.4)         0.845
  Sex                                                                                                                           
  Female (n=360)                                57                        20 (35.1)         18 (31.6)         19 (33.3)         0.486
  Male (n=225)                                  23                        9 (39.1)          6 (26.1)          8 (34.8)          0.899
  Age (years)                                                                                                                   
  \<40 (n=96)                                   19                        8 (42.1)          4 (21.1)          7 (36.8)          0.502
  \>40 (n=489)                                  61                        21 (34.4)         20 (32.8)         20 (32.8)         0.929
  BMI (kg/m^2^)                                                                                                                 
  \<25 (n=289)                                  41                        15 (36.6)         11 (26.8)         15 (36.6)         0.681
  25-30 (n=220)                                 28                        11 (39.3)         9 (32.1)          8 (28.6)          0.698
  \>30 (n=76)                                   11                        3 (27.2)          4 (36.4)          4 (36.4)          0.553
  Sphincterotomy                                                                                                                
  No (n=58)                                     8                         5 (62.5)          0 (0)             3 (37.5)          0.278
  Precut papillotomy (n=74)                     10                        3 (30)            4 (40)            3 (30)            0.856
  Sphincterotomy (n=453)                        62                        21 (33.9)         20 (32.2)         21 (33.9)         0.841
  Pancreatic duct injection                                                                                                     
  Yes (n=28)                                    10                        4 (40)            3 (30)            3 (30)            0.390
  No (n=351)                                    59                        25 (42.4)         10 (16.9)         24 (40.7)         \<0.001
  ERCP duration (min)                                                                                                           
  1-19 (n=82)                                   8                         4 (50)            3 (37.5)          1 (12.5)          0.501
  20-39 (n=122)                                 41                        14 (34.2)         8 (19.5)          19 (46.3)         0.135
  40-59 (n=154)                                 21                        6 (28.6)          9 (42.8)          6 (28.6)          0.564
  60-80 (n=34)                                  10                        5 (50)            4 (40)            1 (10)            0.110
  Anesthetic drug                                                                                                               
  Midazolam & pethidine (n=188)                 21                        4 (19.1)          5 (23.8)          12 (57.1)         0.172
  Diazepam & pethidine (n=19)                   3                         2 (66.7)          0 (0)             1 (33.3)          0.027
  Diazepam (n=16)                               5                         2 (40)            1 (20)            2 (40)            0.306
  Fentanyl & propofol & midazolam (n=88)        17                        10 (58.8)         7 (41.2)          0 (0)             0.513
  Fentanyl & propofol & lidocaine (n=9)         0                         0 (0)             0 (0)             0 (0)             NC
  General anesthesia (n=5)                      1                         0 (0)             1 (100)           0 (0)             0.171
  Number of attempts to cannulate the papilla                                                                                   
  No (n=204)                                    24                        21 (87.5)         1 (4.2)           2 (8.3)           0.604
  1 (n=53)                                      7                         0 (0)             3 (42.8)          4 (57.2)          0.353
  2 (n=80)                                      7                         1 (14.2)          3 (42.9)          3 (42.9)          0.733
  3 (n=87)                                      13                        1 (7.6)           6 (46.2)          6 (46.2)          0.355
  4≤ (n=161)                                    29                        6 (20.7)          11 (37.9)         12 (41.4)         \<0.001
  Number of CBD cannulation                                                                                                     
  No (n=82)                                     11                        5 (45.5)          2 (18.2)          4 (36.3)          0.330
  1 (n=123)                                     12                        2 (16.6)          5 (41.7)          5 (41.7)          0.670
  2 (n=115)                                     14                        5 (35.7)          4 (28.6)          5 (35.7)          0.972
  3 (n=150)                                     24                        8 (33.3)          7 (29.2)          9 (37.5)          0.900
  4≤ (n=115)                                    19                        9 (47.4)          6 (31.6)          4 (21)            0.650
  Number of pancreatic duct cannulation                                                                                         
  No (n=374)                                    29                        8 (27.6)          9 (31)            12 (41.4)         0.990
  1 (n=73)                                      17                        7 (41.2)          4 (23.5)          6 (35.3)          0.156
  2 (n=60)                                      12                        3 (25)            4 (33.3)          5 (41.7)          0.155
  3 (n=46)                                      11                        4 (36.4)          4 (36.4)          3 (27.2)          0.995
  4≤ (n=32)                                     11                        7 (63.6)          3 (27.3)          1 (9.1)           0.127
  Using pancreatic stent                                                                                                        
  Yes (n=24)                                    8                         0 (0)             3 (37.5)          5 (62.5)          0.183
  No (n=503)                                    62                        29 (46.7)         12 (19.4)         21 (33.9)         0.189
  Juxta-ampullary diverticulum                                                                                                  
  Yes (n=30)                                    5                         0 (0)             3 (60)            2 (40)            0.429
  No (n=507)                                    65                        29 (44.6)         12 (18.5)         24 (36.9)         0.109

Group A, 500 mg rectal suppository naproxen; Group B, 5 mg sublingual isosorbide dinitrate; Group C, 5 mg sublingual isosorbide dinitrate and 500 mg rectal suppository naproxen; NC, not calculated
